The document provides a financial analysis of the healthcare sector, highlighting its outperformance compared to the S&P500 over the last four years. It discusses factors such as improving R&D returns, efficiency gains, and a supportive regulatory environment. The document also notes a significant drop in the Nasdaq Biotech Index (NBI) due to a congressional letter questioning Gilead Sciences' pricing of its hepatitis C drug, Sovaldi. The document warns of potential risks to the sector if Congress focuses on drug pricing.
doj/DataSet10/EFTA01453423.pdf
{"key_people":["Gilead Sciences"],"document_type":"tabular","document_subtype":"financial analysis","key_organizations":["Nasdaq Biotech Index","Gilead Sciences"],"reference_numbers":["DB-SDNY-0110994","SDNY_GM_00257178","EFTA01453423"]}